What is Acurion?
Acurion is at the forefront of precision oncology, based in San Diego. The company specializes in AI-driven image analysis for biomarker detection, extracting clinically actionable insights from conventional pathology images. Its OncoGaze platform offers a distinct advantage over genomic testing by leveraging routine pathology slides, enabling an instantaneous, scalable, and accessible approach to precision medicine. This innovation addresses critical gaps in biomarker testing access and delays, which often hinder optimal treatment selection for cancer patients.
How much funding has Acurion raised?
Acurion has raised a total of $4.3M across 1 funding round:
Seed
$4.3M
Seed (2026): $4.3M with participation from Asian Fund for Cancer Research, National Foundation for Cancer Research, and Mesa Verde
Key Investors in Acurion
Asian Fund for Cancer Research
The Asian Fund for Cancer Research is dedicated to advancing cancer research, with a particular emphasis on cancers prevalent in Asian populations. They support innovative projects aimed at understanding cancer development and treatment, fostering global collaborations to enhance research impact.
National Foundation for Cancer Research
The National Foundation for Cancer Research is a nonprofit organization committed to funding groundbreaking cancer research to find cures. They provide essential financial support to scientists working on novel discoveries in cancer treatment, detection, and prevention.
Mesa Verde
Mesa Verde Venture Partners is an early-stage life sciences venture capital firm focused on partnering with entrepreneurs to build successful companies. They invest in pharmaceuticals, medical devices, diagnostics, life science tools, and digital health, with a strong emphasis on Southern California.
What's next for Acurion?
With this substantial backing, Acurion is poised to expand its reach and impact across multiple advanced cancer types. The company's focus on extracting biomarker insights from standard pathology slides positions it to significantly improve treatment selection and patient outcomes. The strategic investment signals confidence in Acurion's technology and its potential to democratize precision oncology, making advanced diagnostic capabilities more widely available to clinicians and patients alike.
See full Acurion company page
